Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a change in the notional interest of a Principal Director or Manager (PDMR) in the company's American Depositary Shares (ADSs).
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
Material Changes
The filing reports an increase in the notional interest of Mr. D E Troy (SVP & General Counsel) in GSK ADSs. This increase resulted from the re-investment of dividends paid on July 14, 2016, under the Company's 2009 Deferred Annual Bonus Plan. The transaction involved both personal contributions and matching elements.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. It is limited to the mechanics of the reported transaction.
Important Facts for Investors
- Transaction Date: July 14, 2016.
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $43.87 per ADS.
- Total Volume: 686.192 ADSs.
- Executive Involved: Mr. D E Troy, SVP & General Counsel.
- Nature of Trade: Dividend re-investment (personal contribution and matching element) rather than an open market purchase or sale.